O	0	8	Efficacy
O	9	12	and
O	13	19	Safety
O	20	22	of
B-intervention	23	33	Ribociclib
I-intervention	34	38	With
I-intervention	39	48	Letrozole
O	49	51	in
B-location	52	54	US
O	55	63	Patients
O	64	72	Enrolled
O	73	75	in
O	76	79	the
O	80	89	MONALEESA
O	89	90	-
O	90	91	2
O	92	97	Study
O	97	98	.

O	99	101	In
O	102	105	the
O	106	113	Mammary
O	114	122	Oncology
O	123	133	Assessment
O	134	136	of
O	137	143	LEE011
O	143	144	'
O	144	145	s
O	146	147	(
O	147	157	Ribociclib
O	157	158	'
O	158	159	s
O	159	160	)
O	161	169	Efficacy
O	170	173	and
O	174	180	Safety
O	181	182	(
O	182	191	MONALEESA
O	191	192	-
O	192	193	2
O	193	194	)
O	195	200	study
O	200	201	,
O	202	213	combination
O	214	223	treatment
O	224	228	with
O	229	232	the
O	233	242	selective
O	243	252	inhibitor
O	253	255	of
O	256	262	cyclin
O	262	263	-
O	263	272	dependent
O	273	280	kinases
O	281	282	4
O	282	283	/
O	283	284	6
O	285	295	ribociclib
O	296	300	with
O	301	310	letrozole
O	311	324	significantly
O	325	333	improved
O	334	345	progression
O	345	346	-
O	346	350	free
O	351	359	survival
O	360	361	(
O	361	364	PFS
O	364	365	)
O	366	372	versus
O	373	382	letrozole
O	383	388	alone
O	389	391	in
O	392	406	postmenopausal
O	407	412	women
O	413	417	with
O	418	425	hormone
O	426	434	receptor
O	434	435	-
O	435	443	positive
O	444	446	HR
O	446	447	+
O	447	448	/
O	448	452	HER2
O	452	453	-
O	454	462	advanced
O	463	469	breast
O	470	476	cancer
O	477	478	(
O	478	481	ABC
O	481	482	)
O	482	483	.

O	484	490	Herein
O	491	493	we
O	494	501	present
O	502	509	results
O	510	514	from
O	515	518	the
O	519	525	subset
O	526	528	of
O	529	531	US
O	532	540	patients
O	541	549	enrolled
O	550	552	in
O	553	562	MONALEESA
O	562	563	-
O	563	564	2
O	564	565	.

B-eligibility	566	580	Postmenopausal
I-eligibility	581	586	women
I-eligibility	587	591	with
I-eligibility	592	594	HR
I-eligibility	594	595	+
I-eligibility	595	596	/
I-eligibility	596	600	HER2
I-eligibility	600	601	-
I-eligibility	602	605	ABC
I-eligibility	606	613	without
I-eligibility	614	622	previous
I-eligibility	623	632	treatment
I-eligibility	633	636	for
I-eligibility	637	645	advanced
I-eligibility	646	653	disease
O	654	658	were
O	659	669	randomized
O	670	671	(
O	671	672	1
O	672	673	:
O	673	674	1
O	674	675	)
O	676	678	to
O	679	689	ribociclib
O	690	693	600
O	694	696	mg
O	696	697	/
O	697	698	d
O	699	700	(
O	700	701	3
O	702	707	weeks
O	708	710	on
O	710	711	/
O	711	712	1
O	713	717	week
O	718	721	off
O	721	722	)
O	723	727	with
O	728	737	letrozole
O	738	739	2
O	739	740	.
O	740	741	5
O	742	744	mg
O	744	745	/
O	745	746	d
O	747	748	(
O	748	758	continuous
O	758	759	)
O	760	762	or
B-control	763	770	placebo
I-control	771	775	with
I-control	776	785	letrozole
O	785	786	.

O	787	790	The
O	791	798	primary
O	799	802	end
O	803	808	point
O	809	812	was
B-outcome-Measure	813	820	locally
I-outcome-Measure	821	829	assessed
I-outcome-Measure	830	833	PFS
O	833	834	.

O	835	842	Overall
O	842	843	,
B-total-participants	844	847	213
O	848	850	US
O	851	859	patients
O	860	864	were
O	865	873	enrolled
O	874	876	in
O	877	886	MONALEESA
O	886	887	-
O	887	888	2
O	889	890	(
O	890	900	ribociclib
O	900	901	,
O	902	903	n
O	904	905	=
B-intervention-participants	906	909	100
O	909	910	;
O	911	918	placebo
O	918	919	,
O	920	921	n
O	922	923	=
B-control-participants	924	927	113
O	927	928	)
O	928	929	.

O	930	938	Baseline
O	939	954	characteristics
O	955	959	were
O	960	967	similar
O	968	975	between
O	976	985	treatment
O	986	992	groups
O	993	996	and
O	997	1007	consistent
O	1008	1012	with
O	1013	1016	the
O	1017	1023	global
O	1024	1034	population
O	1034	1035	.

O	1036	1040	With
O	1041	1042	a
O	1043	1049	median
O	1050	1056	follow
O	1056	1057	-
O	1057	1059	up
O	1060	1062	of
O	1063	1065	27
O	1066	1072	months
O	1072	1073	,
O	1074	1076	38
O	1077	1078	(
O	1078	1080	38
O	1080	1081	%
O	1081	1082	)
O	1083	1086	and
O	1087	1089	29
O	1090	1091	(
O	1091	1093	26
O	1093	1094	%
O	1094	1095	)
O	1096	1104	patients
O	1105	1107	in
O	1108	1111	the
O	1112	1122	ribociclib
O	1123	1126	and
O	1127	1134	placebo
O	1135	1141	groups
O	1141	1142	,
O	1143	1155	respectively
O	1155	1156	,
O	1157	1160	had
O	1161	1170	continued
O	1171	1173	to
O	1174	1181	receive
O	1182	1191	treatment
O	1191	1192	.

B-outcome	1193	1199	Median
I-outcome	1200	1203	PFS
O	1204	1207	was
B-iv-cont-median	1208	1210	27
I-iv-cont-median	1210	1211	.
I-iv-cont-median	1211	1212	6
I-iv-cont-median	1213	1219	months
O	1220	1224	with
O	1225	1235	ribociclib
O	1236	1239	and
B-cv-cont-median	1240	1242	15
I-cv-cont-median	1242	1243	.
I-cv-cont-median	1243	1244	0
I-cv-cont-median	1245	1251	months
O	1252	1256	with
O	1257	1264	placebo
O	1265	1266	(
O	1266	1272	hazard
O	1273	1278	ratio
O	1278	1279	,
O	1280	1281	0
O	1281	1282	.
O	1282	1284	53
O	1284	1285	)
O	1285	1286	.

O	1287	1290	The
O	1291	1295	most
O	1296	1302	common
O	1303	1306	all
O	1306	1307	-
O	1307	1312	cause
O	1313	1320	adverse
O	1321	1327	events
O	1328	1332	were
B-outcome	1333	1344	neutropenia
O	1345	1346	(
O	1346	1356	ribociclib
O	1356	1357	,
B-iv-bin-percent	1358	1360	72
I-iv-bin-percent	1360	1361	.
I-iv-bin-percent	1361	1362	0
I-iv-bin-percent	1362	1363	%
O	1364	1365	[
O	1365	1366	n
O	1367	1368	=
B-iv-bin-abs	1369	1371	72
O	1371	1372	]
O	1372	1373	;
O	1374	1381	placebo
O	1381	1382	,
B-cv-bin-percent	1383	1384	4
I-cv-bin-percent	1384	1385	.
I-cv-bin-percent	1385	1386	6
I-cv-bin-percent	1386	1387	%
O	1388	1389	[
O	1389	1390	n
O	1391	1392	=
B-cv-bin-abs	1393	1394	5
O	1394	1395	]
O	1395	1396	)
O	1396	1397	,
B-outcome	1398	1404	nausea
O	1405	1406	(
O	1406	1416	ribociclib
O	1416	1417	,
B-iv-bin-percent	1418	1420	69
I-iv-bin-percent	1420	1421	.
I-iv-bin-percent	1421	1422	0
I-iv-bin-percent	1422	1423	%
O	1424	1425	[
O	1425	1426	n
O	1427	1428	=
B-iv-bin-abs	1429	1431	69
O	1431	1432	]
O	1432	1433	;
O	1434	1441	placebo
O	1441	1442	,
B-cv-bin-percent	1443	1445	44
I-cv-bin-percent	1445	1446	.
I-cv-bin-percent	1446	1447	0
I-cv-bin-percent	1447	1448	%
O	1449	1450	[
O	1450	1451	n
O	1452	1453	=
B-cv-bin-abs	1454	1456	48
O	1456	1457	]
O	1457	1458	)
O	1458	1459	,
O	1460	1463	and
B-outcome	1464	1471	fatigue
O	1472	1473	(
O	1473	1483	ribociclib
O	1483	1484	,
B-iv-bin-percent	1485	1487	60
I-iv-bin-percent	1487	1488	.
I-iv-bin-percent	1488	1489	0
I-iv-bin-percent	1489	1490	%
O	1491	1492	[
O	1492	1493	n
O	1494	1495	=
B-iv-bin-abs	1496	1498	60
O	1498	1499	]
O	1499	1500	;
O	1501	1508	placebo
O	1508	1509	,
B-cv-bin-percent	1510	1512	50
I-cv-bin-percent	1512	1513	.
I-cv-bin-percent	1513	1514	5
I-cv-bin-percent	1514	1515	%
O	1516	1517	[
O	1517	1518	n
O	1519	1520	=
B-cv-bin-abs	1521	1523	55
O	1523	1524	]
O	1524	1525	)
O	1525	1526	.

O	1527	1530	Two
O	1531	1539	patients
O	1540	1541	(
O	1541	1551	ribociclib
O	1551	1552	,
B-iv-bin-percent	1553	1554	2
I-iv-bin-percent	1554	1555	.
I-iv-bin-percent	1555	1556	0
I-iv-bin-percent	1556	1557	%
O	1557	1558	;
O	1559	1566	placebo
O	1566	1567	,
B-cv-bin-percent	1568	1569	0
I-cv-bin-percent	1569	1570	%
O	1570	1571	)
O	1572	1583	experienced
B-outcome	1584	1591	febrile
I-outcome	1592	1603	neutropenia
O	1603	1604	.

O	1605	1607	In
O	1608	1611	the
O	1612	1614	US
O	1615	1621	subset
O	1622	1624	of
O	1625	1634	MONALEESA
O	1634	1635	-
O	1635	1636	2
O	1636	1637	,
O	1638	1648	ribociclib
O	1649	1653	with
O	1654	1663	letrozole
O	1664	1670	showed
O	1671	1679	superior
B-outcome	1680	1688	efficacy
O	1689	1695	versus
O	1696	1705	letrozole
O	1706	1711	alone
O	1711	1712	.

O	1713	1718	These
O	1719	1727	findings
O	1728	1731	are
O	1732	1742	consistent
O	1743	1747	with
O	1748	1751	the
O	1752	1758	global
O	1759	1769	population
O	1770	1773	and
O	1774	1781	support
O	1782	1787	first
O	1787	1788	-
O	1788	1792	line
O	1793	1796	use
O	1797	1799	of
O	1800	1810	ribociclib
O	1811	1815	with
O	1816	1825	letrozole
O	1826	1828	in
O	1829	1837	patients
O	1838	1842	with
O	1843	1845	HR
O	1845	1846	+
O	1846	1847	/
O	1847	1851	HER2
O	1851	1852	-
O	1853	1856	ABC
O	1856	1857	.
